trending Market Intelligence /marketintelligence/en/news-insights/trending/RPHs1fjr8U_plLBHwW8LmQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Bristol-Myers extends date of debt exchange offers related to Celgene merger

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Bristol-Myers extends date of debt exchange offers related to Celgene merger

Bristol-Myers Squibb Co. has extended the expiration date of offers to exchange notes issued by Celgene Corp. for up to $19.85 billion of new notes and cash.

The New York-based pharmaceutical giant started the exchange offers in connection with its acquisition of Celgene for $95 billion.

The offers will now expire July 8 instead of June 3. Bristol-Myers said the expiration date of the exchange offers may be further extended and the company will give notice of any such extension.

The exchange offer is subject to certain conditions including the closing of the Celgene transaction, which is expected in the third quarter.